Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176476 | 0.86 | CYP1A2 (0.48) | LOXL2CYP1A2FAAHATG4BADORA2A | |
| SCHEMBL19431360 | 0.82 | CYP19A1 (0.44) | SSTR4TACR1 | |
| SCHEMBL3739597 | 0.82 | HTR1A (0.49) | CYP1A2KDRFLT1RETMAP3K20 | |
| SCHEMBL269209 | 0.81 | LOXL2 (0.55) | LOXL2CYP1A2FAAHCYP3A4HTR1A | |
| SCHEMBL9400132 | 0.78 | PTPN1 (0.49) | KDRMAP3K20HDAC6PTPN1PTPN11 | |
| SCHEMBL13035844 | 0.74 | L3MBTL1 (0.52) | LOXL2CYP1A2FAAHATG4BADORA2A | |
| SCHEMBL27669528 | 0.73 | CYP1A2 (0.46) | LOXL2CYP1A2FAAHATG4BADORA2A | |
| SCHEMBL3733711 | 0.73 | MAPT (0.44) | LOXL2CYP1A2FAAHATG4BADORA2A | |
| SCHEMBL5177349 | 0.73 | LOXL2 (0.43) | LOXL2CYP1A2FAAHATG4BADORA2A | |
| SCHEMBL2937018 | 0.72 | CYP1A2 (0.54) | LOXL2CYP1A2FAAHATG4BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| EP-3188729-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016036796-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016036796-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-1773808-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-02-16 | — | — | EP | disclosed |
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| US-7759379-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1773828-A1 | HETEROCYCLE -SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773808-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-04-18 | — | — | EP | disclosed |
| CN-1768054-A | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA SA (FR) | 2006-05-03 | — | — | CN | disclosed |
| WO-2006010641-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010642-A1 | HETEROCYCLE-SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-02-02 | — | — | WO | disclosed |
| EP-1621535-A1 | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
| EP-1621539-A1 | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
| EP-1621536-A1 | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | NGF, NTRK1, TK1 | LOXL2 4546/4885CYP1A2 4827/4885FAAH 2593/4885 |
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | LOXL2 3568/4885CYP1A2 803/4885FAAH 3940/4885 |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | PRKG1, PRKACA, PRKCA | LOXL2 4473/4885CYP1A2 3012/4885FAAH 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.